Spire Healthcare Group (LON:SPI) Sets New 52-Week High Following Analyst Upgrade

Shares of Spire Healthcare Group plc (LON:SPI) hit a new 52-week high on Thursday after Berenberg Bank raised their price target on the stock from GBX 286 to GBX 300. Berenberg Bank currently has a buy rating on the stock. Spire Healthcare Group traded as high as GBX 252.50 ($3.14) and last traded at GBX 248 ($3.09), with a volume of 3522562 shares trading hands. The stock had previously closed at GBX 238.50 ($2.97).

Separately, JPMorgan Chase & Co. restated an “overweight” rating and issued a GBX 295 ($3.67) price objective on shares of Spire Healthcare Group in a report on Monday, February 26th.

Spire Healthcare Group Stock Performance

The firm has a 50-day moving average price of GBX 237.57 and a two-hundred day moving average price of GBX 228.97. The company has a quick ratio of 0.74, a current ratio of 0.69 and a debt-to-equity ratio of 170.37. The firm has a market cap of £1.00 billion, a PE ratio of 3,542.86, a P/E/G ratio of 1.06 and a beta of 0.99.

Spire Healthcare Group Increases Dividend

The company also recently disclosed a dividend, which will be paid on Friday, June 21st. Shareholders of record on Thursday, May 23rd will be given a GBX 2.10 ($0.03) dividend. The ex-dividend date is Thursday, May 23rd. This is an increase from Spire Healthcare Group’s previous dividend of $0.50. This represents a dividend yield of 0.89%. Spire Healthcare Group’s dividend payout ratio is currently 4,285.71%.

Spire Healthcare Group Company Profile

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.